Totaligent acquires Aetherium Medical ($10M rev); Klarich President, board member

Totaligent, Inc.

Totaligent forms subsidiary Aetherium Medical LLC; Klarich contributes trade secrets, know-how, and business network.
Ivan Klarich appointed President immediately, will join 3-member Board after closing.
Initial 10% fully-diluted equity (Series D Preferred) issued at closing; additional milestone-based equity.
Underlying Aetherium platform generated ~$10M annual revenue with >15 years consistent profitability.
No cash consideration; equity-only. Separate GloMed JV is not a condition of this agreement.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Totaligent, Inc. entered into Definitive Agreement with Ivan Klarich (effective 2026-04-10).

Action: entry
Agreement: asset purchase
Counterparty: Ivan Klarich
Effective: 2026-04-10

Exact text from the filing

On April 10, 2026, Totaligent, Inc. (the “Company”) entered into a Definitive Agreement (the “Definitive Agreement”) with Ivan Klarich (“Klarich”).

View on SEC.gov

22 material agreements filed in the last 30 days. Browse all material agreements →

Totaligent, Inc. filing history →

Source: SEC EDGAR

accession 0001477932-26-002227

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.